Gilles Gallant

Gilles joined Mythic Therapeutics in August 2022, assuming responsibility for the strategy, direction, and execution of the company’s clinical development program.

Gilles joins Mythic from Daiichi Sankyo, where he was Senior Vice President Global Head of Oncology Clinical Development and led the development of the company’s global oncology portfolio. At Daiichi, he built and led the team that guided the clinical development, the global regulatory submission and worldwide approval of the antibody-drug conjugate Enhertu® for the treatment of patients with advanced breast cancer, gastric cancer and lung cancer (NSCLC).

Gilles previously held leadership roles of increasing responsibility in clinical oncology at Bristol-Myers-Squibb, Human Genome Sciences and Biomarin. He designed and led clinical trials of Bristol-Myers-Squibb oncology pipeline resulting in the worldwide approval of three indications (lung, breast, and ovarian cancer) for the blockbuster Taxol®, as well as the development strategy and clinical implementation for all oncology and hematology assets at Human Genome Sciences and later at BioMarin Pharmaceutical leading to the approval of Talzenna(TM).

He received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montréal in Québec, Canada and is a Fellow of the Order of Pharmacists of Québec (FOPQ).